NMS · —

Autolus Therapeutics plc (AUTL) Stock

$1.46 -13.61% NMS: AUTL —

—

Valuation

MetricValue
Price$1.46
Market Cap—
P/E Ratio-1.35
P/B Ratio—
P/S Ratio—
EPS (TTM)$-1.08
52-Week High$2.70
52-Week Low$1.18
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-161.80%
ROA-48.90%
ROCE-52.52%
Gross Margin-361.33%
Operating Margin-361.33%
Net Margin-384.00%
Debt/Equity0.00
Current Ratio5.97

Annual Financials (USD)

Metric20212022202320242025
Revenue——$2.0M$10.0M$75.0M
Operating Profit$-141.0M$-143.0M$-180.0M$-241.0M$-271.0M
Net Profit$-142.0M$-149.0M$-208.0M$-221.0M$-288.0M
EPS$-1.97$-1.57$-1.20$-0.86$-1.08
Op Margin——-10583.0%-2386.0%-359.0%

Balance Sheet (USD)

Metric20222022202320242025
Total Assets$364.0M$364.0M$375.0M$783.0M$589.0M
Total Liabilities$93.0M$93.0M$264.0M$355.0M$411.0M
Cash$269.0M$269.0M$240.0M$227.0M$104.0M
Borrowings—————

Latest News

Autolus Therapeutics (AUTL) Grants Inducement Awards to New Employees Insider Monkey · Jul 14, 2026 European Equities Traded in the US as American Depositary Receipts Decline Friday MT Newswires · Jul 10, 2026 European Equities Traded in the US as American Depositary Receipts Decline Sharply in Wednesday Trading MT Newswires · Jul 8, 2026 European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading MT Newswires · Jul 7, 2026 European Equities Traded in the US as American Depositary Receipts Rise Sharply in Thursday Trading MT Newswires · Jul 2, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-118.0M$-112.0M$-146.0M$-206.0M$-284.0M
Investing Cash Flow$-9.0M$-11.0M$-11.0M$-395.0M$158.0M
Financing Cash Flow$284.0M$224.0M$-1.0M$590.0M$-4.0M
Net Cash Flow$157.0M$100.0M$-157.0M$-11.0M$-129.0M
Free Cash Flow$-127.0M$-123.0M$-157.0M$-228.0M$-303.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield—
Quick Ratio5.52
Interest Coverage-7.32
Return 1Y-40.16%
Return 3Y-41.60%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALLOAllogene Therapeutics, Inc. $1.47 +4.64% -2.24 $505.65M 0.00%
ATRAAtara Biotherapeutics, Inc. $9.45 +2.38% -7.94 $85.15M 0.00%
CLLSCellectis S.A. $2.81 -2.26% -4.14 $282.17M 0.00%
CRBUCaribou Biosciences, Inc. $0.48 -0.52% -1.13 $47.48M 0.00%
DTILPrecision BioSciences, Inc. $6.79 +5.52% -2.26 $187.28M 0.00%

About Autolus Therapeutics plc

—

the stock is valued at a price-to-earnings (P/E) ratio of -1.35. Over the past 52 weeks the stock has ranged between $1.18 and $2.70, and currently trades 45.9% below its 52-week high.

On profitability, Autolus Therapeutics plc generates a return on equity (ROE) of -161.80%, return on capital employed of -52.52%, an operating margin of -361.33%, a net profit margin of -384.00%.

Related — Stocks

USDE StablecoinX Inc. $1.00 -0.01% DPC DPC Holdings PLC $39.51 +1.73% JMKE Jersey Mike's Subs Inc. $17.21 -0.52% WCCB West Coast Community Bancorp $61.05 -0.18% KRSA Korsana Biosciences, Inc. $34.92 +4.19%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Screens featuring this stock

High ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
Run Stock Screener Investing Guides